Hence, even if LKB1 mutation does not confer resistance to BAY 1238097, our results reinforce the correlation of wild type LKB1 and the susceptibility to MYC downregulation upon BET inhibition, which appears to predispose cells to a higher anti-tumorigenic effect compared to impaired MYC downregulation due to LKB1 mutations, at least in NSCLC. The gene discussed is STK11; the disease is non-small cell lung carcinoma.